Mirikizumab Levels in Breast Milk During Treatment
Treatments studied
Part of Digestive system clinical trials.
This study measures how much of the medication mirikizumab passes into breast milk when mothers take it for their approved medical condition. The goal is to understand if it's safe for breastfeeding infants when mothers are receiving this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and your infant is at least 3 weeks old
- You have been exclusively breastfeeding your infant with well-established milk supply
- You have received at least 2 doses of mirikizumab injections (one every 4 weeks) before the study starts
- You are taking mirikizumab for a health condition that your doctor approved
- Your infant can feed from a bottle using stored breast milk or formula
- You and your infant are in good health with no conditions that would make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This study is testing a new medicine called mirikizumab in healthy people to see how it works in the body. Healthy volunteers help researchers understand the drug's safety before it is studied in patients with a disease.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.